Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections

Description

Pathogenica and Life Technologies EMEA Partner to Control Hospital Acquired Infections PR Newswire GLASGOW, Scotland, September 19, 2012 GLASGOW, Scotland, September 19, 2012 /PRNewswire/ -- Companies to co-market Pathogenica's HAI BioDetection Kits through exclusive agreement in Europe, the Middle East and Africa Life Technologies (NASDAQ: LIFE) announced an exclusive agreement with Pathogenica, Boston, Massachusetts, to co-market and distribute for research use, the Pathogenica HAI (Hospital Acquired Infection) BioDetection Kit on the [TM]Ion Torrent PGM in Europe, the Middle East and Africa (EMEA). [TM] [TM]Based on Pathogenica's DxSeq technologyand the Ion Torrent sequencing platform, the kit enables identification of pathogens with high accuracy, at high specific strain resolution and at a scale that could make hospital-wide testing practical. "Hospital acquired infections are becoming an increasingly serious health risk for patients and present significant economic issues for hospitals," said Peter Silvester, President, Life Technologies EMEA. "The combination of [TM]Pathogenica's technology with the Ion Torrent PGM will provide a solution that can help address this problem by enabling hospitals to quickly detect these types of infections with extreme accuracy." Pathogenica's analysis software provides simple, concise output reports that indicate which species and strains are present and at what levels.

Informations

• Publié par: life-technologies-and-pathogenica
• Nombre de lectures: 20
• Langue: English

Extrait

Pathogenica and Life Technologies EMEA

Partner to Control Hospital Acquired Infections

PR Newswire

GLASGOW, Scotland, September 19, 2012

GLASGOW, Scotland

,

September 19, 2012

/PRNewswire/ --

Companies to co-market Pathogenica's HAI BioDetection Kits

through exclusive agreement in Europe, the Middle East and Africa

Life Technologies (NASDAQ: LIFE) announced an exclusive agreement with

Pathogenica,

Boston, Massachusetts

, to co-market and distribute for research

use, the Pathogenica HAI (Hospital Acquired Infection) BioDetection Kit on the

Ion Torrent PGM

[

TM]

in

Europe

, the

Middle East

and

Africa

(EMEA).

Based on Pathogenica's DxSeq

[TM]

technologyand the Ion Torrent

[TM]

sequencing platform, the kit enables identification of pathogens with high

accuracy, at high specific strain resolution and at a scale that could make

hospital-wide testing practical.

"Hospital acquired infections are becoming an increasingly serious health risk

for patients and present significant economic issues for hospitals," said Peter

Silvester, President, Life Technologies EMEA. "The combination of

Pathogenica's technology with the Ion Torrent PGM

[TM]

will provide a solution

that can help address this problem by enabling hospitals to quickly detect these

types of infections with extreme accuracy."

Pathogenica's analysis software provides simple, concise output reports that

indicate which species and strains are present and at what levels. These kits

are not for use in the diagnosis of hospital patients.

Current methods for detecting causative organisms can take days for results or

are limited to a few pathogens. The Pathogenica/Life Technologies HAI solution

quickly and cost-effectively identifies not only what species are present in a

sample, but also provides high-resolution sequence data that includes strain

identity and resistance genes, which is critical information for understanding

and containing or preventing HAI outbreaks. Pathogenica's kit can detect more

than 12 pathogenic bacteria and 15 resistance gene families in a single assay

and up to 12 samples can be tested per sequencing run. Dozens of samples

can simultaneously be tested in one day with results in an impressive

timeframe of less than 12 hours.

The companies are evaluating an opportunity to pursue CE marking together

for use of the kit as an in-vitro diagnostic assay.

"As we enter yet another market with Life Technologies as our partner, it is

gratifying that together we are helping to make hospitals safer around the

world," said Yemi Adesokan, co-founder and CEO of Pathogenica. "The Ion

Torrent

[TM]

PGM has continued to expand its installed base and is an excellent

complement to our technology and our mission of making next-generation

sequencing relevant and accessible to clinicians."

Each Pathogenica kit provides reagents for identification of the following

pathogens and drug resistance markers per sample:

Acinetobacter baumannii,

Clostridium difficile, Escherichia coli, Enterococcus faecalis, Enterococcus

faecium, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella

pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa,

Coagulase negative

Staph (S.epidermidis, S.saprophyticus), Staphylococcus aureus

, common beta-

lactamase resistance genes, mecA, and the vanA gene family. The technology

allows for fast modification to incorporate the detection of emerging

pathogenic fungi, viruses and resistances.

All products referenced are for Research Use Only. Not intended for diagnostic

uses.

About Pathogenica

Pathogenica combines the power of Cloud-based DNA sequencing analysis and

next-generation DNA sequencing to revolutionize pathogen identification and

enable real-time bio-surveillance. Its DxSeq™ platform offers new applications

in health services through rapid multiplex identification of pathogens and drug

resistance genes; providing personalized diagnosis for infectious diseases that

allows for more effective diagnosis and treatment of patients. Pathogenica's

high throughput pathogen identification system performs rapid and highly

sensitive identification of a wide variety of biomarkers using just a common

assay protocol.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology

company with customers in more than 160 countries using its innovative

solutions to solve some of today's most difficult scientific challenges. Quality

and innovation are accessible to every lab with its reliable and easy-to-use

solutions spanning the biological spectrum with more than 50,000 products for

translational research, molecular medicine and diagnostics, stem cell-based

therapies, forensics, food safety and animal health. Its systems, reagents and

consumables represent some of the most cited brands in scientific research

including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion,

Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs

approximately 10,400 people and upholds its ongoing commitment to

innovation with more than 4,000 patents and exclusive licenses. LIFE had sales

of

$3.7 billion

in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated

results that involve risks and uncertainties. Some of the information contained

in this press release, including, but not limited to, statements as to industry

trends and Life Technologies' plans, objectives, expectations and strategy for its

business, contains forward-looking statements that are subject to risks and

uncertainties that could cause actual results or events to differ materially from

those expressed or implied by such forward-looking statements. Any

statements that are not statements of historical fact are forward-looking

statements. When used, the words "believe," "plan," "intend," "anticipate,"

"target," "estimate," "expect" and the like, and/or future tense or conditional

constructions ("will," "may," "could," "should," etc.), or similar expressions,

identify certain of these forward-looking statements. Important factors which

could cause actual results to differ materially from those in the forward-looking

statements are detailed in filings made by Life Technologies with the Securities

and Exchange Commission. Life Technologies undertakes no obligation to

update or revise any such forward-looking statements to reflect subsequent

events or circumstances.